rs6031551 — HNF4A HNF4A Regulatory Variant

HNF4A P2 Haplotype — Beta-Cell Regulation and Metabolic Risk

HNF4A¹¹ HNF4A
Hepatocyte Nuclear Factor 4 Alpha — a nuclear receptor transcription factor expressed in liver, intestine, kidney, and pancreatic beta cells. Controls dozens of genes governing glucose production, fatty acid oxidation, and cholesterol transport is a master regulator of metabolic gene expression. The gene operates from two distinct promoters: P1, active in adult liver, and P2, active in pancreatic beta cells and fetal liver, each driving different isoforms (HNF4A1–6 from P1; HNF4A7–12 from P2). rs6031551 lies within an intronic region of HNF4A on chromosome 20q13.12, 80 base pairs from the closely related variant rs6031552, and falls inside the same haplotype block surrounding the HNF4A P2 promoter. It was genotyped as one of nine HNF4A SNPs in a direct study of insulin resistance by Saif-Ali et al. 2011²² Saif-Ali et al. 2011
Saif-Ali R et al. Hepatocyte nuclear factor 4 alpha P2 promoter variants associate with insulin resistance. Acta Biochim Pol, 2011.

The Mechanism

The P2 promoter drives the "fetal" HNF4A isoform, normally silenced in adult liver but persistently active in pancreatic beta cells throughout life. Variants in the P2 haplotype block modestly alter promoter activity and the amount of this isoform produced. In the pancreas, dysregulation of P2-driven HNF4A levels impairs glucose-stimulated insulin secretion³³ glucose-stimulated insulin secretion
GSIS — the key mechanism by which beta cells detect rising blood glucose and release insulin proportionally, the fundamental mechanism of beta-cell function. In the diabetic liver, the P2 isoform becomes aberrantly re-expressed: a glucagon-TET3-FOXA2 epigenetic axis⁴⁴ glucagon-TET3-FOXA2 epigenetic axis
Glucagon stimulates TET3 expression → TET3 demethylates the P2 promoter → P2 isoform transcription rises → excess hepatic glucose output compounds hyperglycemia activates P2 transcription, driving excess hepatic glucose output on top of impaired beta-cell insulin release.

rs6031551 is an intronic variant that does not alter protein sequence. It is 80 bp from the closely related rs6031552 and was genotyped as part of the same nine-SNP P2 haplotype panel. Both SNPs tag the broader P2 haplotype block and capture overlapping biological signal, but their independent functional contributions have not been resolved.

The Evidence

rs6031551 was directly genotyped in 160 Malaysian subjects without diabetes by Saif-Ali et al. 2011⁵⁵ 160 Malaysian subjects without diabetes by Saif-Ali et al. 2011
Nine HNF4A SNPs studied; the CCCGTC P2 haplotype associated with higher insulin resistance (HOMA-IR, p=0.022) and lower HDL (p=0.001). Acta Biochim Pol, 2011 as part of a nine-SNP HNF4A panel. The P2 haplotype block that rs6031551 tags was associated with elevated insulin resistance (HOMA-IR, p=0.022) and lower HDL cholesterol (p=0.001), indicating that pre-diabetic metabolic perturbations are present in haplotype carriers before overt diabetes develops. The three P2 promoter SNPs within the panel (rs4810424, rs1884613, rs1884614) showed the strongest individual signals; rs6031551 contributed to the haplotype-level association.

The broader P2 haplotype literature, derived from studies of overlapping SNPs, found modest but replicated associations with type 2 diabetes: a UK replication in 5,256 subjects⁶⁶ UK replication in 5,256 subjects
Weedon MN et al. Common variants of the HNF-4alpha P2 promoter are associated with type 2 diabetes in the UK. Diabetes, 2004 yielded OR 1.15 (P=0.02), while a Scandinavian meta-analysis of 4,000 cases and 7,571 controls⁷⁷ Scandinavian meta-analysis of 4,000 cases and 7,571 controls
Johansson S et al. Studies in 3,523 Norwegians and meta-analysis in 11,571 subjects indicate HNF4A P2 region variants are associated with type 2 diabetes. Diabetes, 2007 confirmed a pooled OR of 1.14 (95% CI 1.06–1.23, P=0.0004). A critical caveat from Barroso et al. 2008⁸⁸ Barroso et al. 2008
Population-specific risk of type 2 diabetes conferred by HNF4A P2 promoter variants: a lesson for replication studies. Diabetes, 2008 is that the haplotype risk is population-specific: OR ~1.7 in Ashkenazi subjects versus OR 1.04 (NS) in UK individuals, meaning the tag SNPs vary in their linkage disequilibrium with the true causal variant across ancestries.

The evidence for rs6031551 specifically is classified as emerging: the variant was genotyped in only one direct study (small sample, n=160), its independent effect cannot be separated from other P2 haplotype SNPs, and it has no independent GWAS signal or ClinVar entry.

Practical Actions

The C allele at rs6031551 tags the HNF4A P2 risk haplotype. For carriers, the primary concern is impaired glucose-stimulated insulin secretion and associated insulin resistance, reflected in the Saif-Ali 2011 findings of elevated HOMA-IR and lower HDL in non-diabetic haplotype carriers. Periodic monitoring of fasting glucose, HbA1c, and HDL cholesterol can detect early dysglycemia and lipid changes before they progress to overt disease. Choosing lower-glycemic-index carbohydrates reduces the postprandial beta-cell demand that the P2 haplotype is least equipped to meet.

Interactions

rs6031551 is in strong linkage disequilibrium with rs6031552 (80 bp away), rs1884613, rs2144908, rs4810424, and rs1884614 — all intronic or near-promoter variants within the same HNF4A P2 haplotype block. These SNPs capture overlapping biological signal and do not represent independent cumulative risk. The P2 pathway intersects with KCNJ11 (rs5219, KATP channel) and TCF7L2 (rs7903146, Wnt/incretin signaling), both of which also impair beta-cell insulin secretion through separate mechanisms. Carriers of the HNF4A P2 risk haplotype with additional KCNJ11 or TCF7L2 risk alleles accumulate multiple beta-cell secretory deficits, a profile warranting earlier and more frequent glucose monitoring.